SCYNEXIS, Inc. (SCYX)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.4M | 334K | 18.6M | 0.00 |
| Gross Profit | ||||
| Operating Income | -9.6M | -8.4M | 10.5M | -16.9M |
| Net Income | -6.9M | -8.6M | 12.3M | -21.3M |
| Diluted EPS | $-1.12 | $-1.36 | $nan | $-3.36 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 5.1M | 140.1M | 3.7M | 20.6M |
| Gross Profit | 4.5M | 124.5M | 3.7M | |
| Operating Income | -85.8M | 72.7M | -37.1M | -16.1M |
| Net Income | -62.8M | 67.0M | -21.3M | -8.6M |
| Diluted EPS | $-11.76 | $11.12 | $-3.52 | $-1.36 |